EPCAM and ovarian carcinoma: The first treatment that aims to target the previously identified ovarian cancer-associated antigens [including NY-ESO-1, CA 125 (MUC16), MUC1 and epithelial cell adhesion molecule (EpCAM)] with mAbs [55] or with new engineered bispecific antibodies and bispecific/trispecific killer engagers (BiKEs or TriKEs), which are molecules that crosslink tumor cells antigens (e.g., EpCAM) with CD16 on NK cells, thus activating/enhancing ADCC [86,87].